Original articleLiver, pancreas, and biliary tractLong-term Efficacy and Safety of Lamivudine, Entecavir, and Tenofovir for Treatment of Hepatitis B Virus–Related Cirrhosis
Section snippets
Materials and Methods
This retrospective study enrolled adult patients with chronic hepatitis B–associated cirrhosis treated with antiviral therapy beginning from 2005 in 18 centers throughout Turkey. The study protocol was approved by the Ethics Committee of the Ankara Education and Research Hospital before study initiation. To be eligible, living patients had to use any antivirals for more than 12 months after a diagnosis of cirrhosis. Patients had to have basal and last visit clinical and laboratory outcomes.
Patient Demographics
All HBV-associated cirrhosis patients diagnosed after the beginning of 2005 were enrolled. In all, 227 patients were included. Seventy-two, 77, and 74 patients were initiated with tenofovir, entecavir, or lamivudine, respectively. Adefovir was the choice for the remaining patients. Demographic data and baseline laboratory test results of all patients are summarized in Table 1. Among 227 patients, 51 had liver biopsies. A total of 104 patients had at least one of the components of decompensated
Discussion
In this study we showed that entecavir and tenofovir have better long-term biochemical outcomes than lamivudine in HBV-related advanced cirrhosis. However, clinical outcomes with respect to cirrhosis-related complications were comparable. All had a low adverse event frequency, however, as expected, lamivudine had a higher resistance rate as in noncirrhotic patients. Tenofovir and entecavir provided better long-term improvement or stabilization of liver functions in decompensated cirrhosis.
All
References (26)
- et al.
Survival and prognostic indicators in hepatitis B surface antigen-positive cirrhosis of the liver
Gastroenterology
(1992) - et al.
Lamivudine treatment in patients with severely decompensated cirrhosis due to replicating hepatitis B infection
J Hepatol
(2000) - et al.
Determinants of early mortality in patients with decompensated chronic hepatitis B treated with antiviral therapy
Gastroenterology
(2002) - et al.
Adefovir dipivoxil therapy for lamivudine-resistant hepatitis B in pre- and post-liver transplantation patients
Hepatology
(2003) - et al.
Efficacy of entecavir in treatment-naive patients with hepatitis B virus-related decompensated cirrhosis
J Hepatol
(2010) - et al.
Two years safety and efficacy of tenofovir disoproxil fumarate (TDF) in patients with HBV-induced cirrhosis
J Hepatol
(2009) - et al.
Management of end-stage liver disease in chronic hepatitis B
Clin Liver Dis
(2010) Entecavir in decompensated HBV cirrhosis: the future is looking brighter
J Hepatol
(2010)- et al.
Lamivudine treatment is beneficial in patients with severely decompensated cirrhosis and actively replicating hepatitis B infection awaiting liver transplantation: a comparative study using a matched, untreated cohort
Hepatology
(2001) - et al.
Beneficial effects of lamivudine in hepatitis B virus-related decompensated cirrhosis
J Hepatol
(2000)
Effect of lamivudine treatment on survival of 309 North American patients awaiting liver transplantation for chronic hepatitis B
Liver Transpl
Treatment of hepatitis B in decompensated liver cirrhosis
Int J Hepatol
Management of chronic hepatitis B
Eur J Gastroenterol Hepatol
Cited by (80)
Effects of Tenofovir vs Entecavir on Risk of Hepatocellular Carcinoma in Patients With CHB: A Comment for Moving Forward
2022, Clinical Gastroenterology and HepatologyEffects of Tenofovir vs Entecavir on Risk of Hepatocellular Carcinoma in Patients With Chronic HBV Infection: A Systematic Review and Meta-analysis
2021, Clinical Gastroenterology and HepatologyCitation Excerpt :The summary of the excluded studies and the reasons for exclusion are described in Supplementary Table 4. Finally, 15 nonrandomized comparative studies evaluating the effect of TDF vs ETV on the risk of HCC development were included in the systematic review and meta-analysis.11–20,23–27 To avoid overlap of the study population among the studies conducted in Korea, Korean national registry data from Choi et al16 were excluded from the analyses.
Factors predicting outcomes of hepatitis B-related cirrhosis patients with long-term antiviral therapy
2020, Journal of the Formosan Medical Association
Conflicts of interest The authors disclose no conflicts.